



CLARITY FA

LEXEO
therapeutics
CLINICAL TRIALS

For individuals living with Friedreich ataxia cardiomyopathy

HELP US GET TO THE HEART OF FA.

CONSIDER THE CLARITY-FA STUDY.

Friedreich ataxia (FA) is a **rare, multi-systemic, genetic** disease that impacts **the nervous system and the heart**.

While most people can recognize the visible signs and symptoms of FA, such as difficulty with movement, muscle weakness, poor muscle control and unsteady balance, the **silent damage to the heart often goes unnoticed**.

Approximately **2/3** of individuals with FA may have a shortened lifespan due to heart-related issues.¹

Even though approximately 80% percent of people with FA develop heart muscle disease,² researchers currently do not know enough about how the heart is impacted by FA. Unfortunately, there currently are no approved treatments for heart disease in FA.

At Lexeo, we have made this unmet need a top priority and are currently researching an investigational gene therapy, called LX2006, in clinical trials.

Lexeo is sponsoring a natural history study called CLARITY-FA to learn more about how heart disease develops and progresses in FA. Your participation can help us advance the science.

What is the CLARITY-FA study?

The goal of the CLARITY-FA study is to learn about how heart disease develops and worsens in individuals with FA. Information gained from participation in this study will provide valuable data to learn more about heart disease in FA. The information will also help advance our gene therapy research.

Who is eligible for the CLARITY-FA study?

- » CLARITY-FA is looking for individuals who have cardiomyopathy associated with FA.
- » The study is open to individuals with genetically confirmed FA diagnosis and evidence of cardiomyopathy based on specific criteria.

CLARITY-FA includes two age groups:

- » Individuals who are at least 16 years of age
 - » Individuals who are between 6 and under 16 years of age
- » Full eligibility criteria will be evaluated by the study doctor to determine if an individual is the right candidate for this study.
 - » It is important to note that participants in the CLARITY-FA natural history study will not receive any investigational study drug.

Participation in the CLARITY-FA study is voluntary. As with any clinical study or trial, there may be risks involved with participation. We encourage any individual considering participation in a clinical study or trial to consult with your physician or medical team.

This is a global study with multiple locations across the U.S.



What is a natural history study and why is it important?

- » In order to develop treatments for a disease, researchers must first learn more about it. A natural history study is a type of research that tracks how a disease develops and changes over time in people who have it.
- » Researchers observe symptoms, changes, and patterns to better learn what to expect from the disease, find ways to diagnose it earlier, and how to manage the disease better.
- » Information from natural history studies provide important knowledge that can help develop better or new treatments for a disease.
- » It is important to note that participants in natural history studies do not receive any investigational study drug as the goal is to learn about the natural course of the disease.

Other information:

- » This study is sponsored by Lexeo Therapeutics, Inc.
- » All study-related assessments will be provided at no cost.
- » You will receive no direct payment for taking part in the study. Participants and their caregiver will be reimbursed for reasonable study-related expenses for travel (e.g., transportation, meals, and hotel, as appropriate).



For more information about the CLARITY-FA study, please visit <https://trials.lexeotx.com> or email clinicaltrials@lexeotx.com



Additional information on study sites and locations can be found at <https://clinicaltrials.gov> (NCT #06865482)